{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:20:34Z","timestamp":1783189234215,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-026-01155-w","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:27:21Z","timestamp":1783142841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoglobulin A nephropathy with superimposed minimal change disease complicated by acute kidney injury requiring temporary hemodialysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Yuki","family":"Nagaike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3941-6432","authenticated-orcid":false,"given":"Akifumi","family":"Tabei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Furukata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Takara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneharu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Hemmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"6","key":"1155_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1155_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10238-019-00580-9","volume":"19","author":"X Han","year":"2019","unstructured":"Han X, Xiao Y, Tang Y, Zheng X, Anwar M, Qin W. Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome. Clin Exp Med. 2019;19(4):479\u201386.","journal-title":"Clin Exp Med"},{"key":"1155_CR3","unstructured":"KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021; 100(4):1-276."},{"issue":"1","key":"1155_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86081-0","volume":"15","author":"L Tan","year":"2025","unstructured":"Tan L, Jin LH, Wang YQ, Chen W, Wen Q. Clinical features, pathological characteristics, and prognosis of patients with IgA nephropathy complicated with nephrotic syndrome. Sci Rep. 2025;15(1):1804.","journal-title":"Sci Rep"},{"key":"1155_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.793511","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Lu W, Li H, Liu X, Zhang X, Xie L, et al. Immune Characteristics of IgA Nephropathy With Minimal Change Disease. Front Pharmacol. 2021;12:793511.","journal-title":"Front Pharmacol"},{"key":"1155_CR6","doi-asserted-by":"crossref","unstructured":"Cho WH, Park SH, Choi SK, Jung SW, Jeong KH, Kim YG, et al. Characterization of IgA Deposition in the Kidney of Patients with IgA Nephropathy and Minimal Change. J Clin Med. 2020;9(8).","DOI":"10.3390\/jcm9082619"},{"key":"1155_CR7","doi-asserted-by":"publisher","first-page":"1105933","DOI":"10.3389\/fneph.2023.1105933","volume":"3","author":"WY Guo","year":"2023","unstructured":"Guo WY, Sun LJ, Dong HR, Wang GQ, Xu XY, Cheng WR, et al. Characterization of patients with IgA nephropathy with and without associated minimal change disease. Front Nephrol. 2023;3:1105933.","journal-title":"Front Nephrol"},{"issue":"5","key":"1155_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.kint.2018.04.024","volume":"94","author":"A Meyrier","year":"2018","unstructured":"Meyrier A, Niaudet P. Acute kidney injury complicating nephrotic syndrome of minimal change disease. Kidney Int. 2018;94(5):861\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"1155_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0756-6","volume":"18","author":"Y Fujigaki","year":"2017","unstructured":"Fujigaki Y, Tamura Y, Nagura M, Arai S, Ota T, Shibata S, et al. Unique proximal tubular cell injury and the development of acute kidney injury in adult patients with minimal change nephrotic syndrome. BMC Nephrol. 2017;18(1):339.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1155_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000507426","volume":"10","author":"Y Oyama","year":"2020","unstructured":"Oyama Y, Iwafuchi Y, Morioka T, Narita I. Acute kidney injury associated with minimal change nephrotic syndrome in an elderly patient successfully treated with both fluid management and specific therapy based on kidney biopsy findings. Case Rep Nephrol Dial. 2020;10(1):42\u201350.","journal-title":"Case Rep Nephrol Dial"},{"key":"1155_CR11","doi-asserted-by":"crossref","unstructured":"Schachter H, McGuire EJ, Roseman S. Sialic acids. 13. A uridine diphosphate D-galactose: mucin galactosyltransferase from porcine submaxillary gland. J Biol Chem. 1971; 246(17):5321\u20138.","DOI":"10.1016\/S0021-9258(18)61909-X"},{"issue":"1","key":"1155_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang SCW, Boor P, Tesa\u0159 V, Floege J, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1):67.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"1155_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206865","volume":"13","author":"Y Wada","year":"2018","unstructured":"Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, et al. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. PLoS ONE. 2018;13(11):e0206865.","journal-title":"PLoS ONE"},{"issue":"12","key":"1155_CR14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/ndt\/gfz152","volume":"35","author":"CA Cassol","year":"2020","unstructured":"Cassol CA, Bott C, Nadasdy GM, Alberton V, Malvar A, Nagaraja HN, et al. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy. Nephrol Dial Transplant. 2020;35(12):2123\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"1155_CR15","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","volume":"44","author":"E Gianos","year":"2024","unstructured":"Gianos E, Duell PB, Toth PP, Moriarty PM, Thompson GR, Brinton EA, et al. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2024;44(12):e304\u201321.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1155_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0288384","volume":"18","author":"TY Wang","year":"2023","unstructured":"Wang TY, Chang FP, Yang AH, Ka SM, Chen A, Hsieh JT, et al. Key pathological features characterize minimal change disease-like IgA nephropathy. PLoS ONE. 2023;18(7):e0288384.","journal-title":"PLoS ONE"},{"issue":"3","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1053\/j.ajkd.2003.10.039","volume":"43","author":"J Vande Walle","year":"2004","unstructured":"Vande Walle J, Mauel R, Raes A, Vandekerckhove K, Donckerwolcke R. ARF in children with minimal change nephrotic syndrome may be related to functional changes of the glomerular basal membrane. Am J Kidney Dis. 2004;43(3):399\u2013404.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1155_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/ki.1984.76","volume":"25","author":"SO Bohman","year":"1984","unstructured":"Bohman SO, Jaremko G, Bohlin AB, Berg U. Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome. Kidney Int. 1984;25(4):696\u2013700.","journal-title":"Kidney Int"},{"issue":"3","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1172\/JCI117435","volume":"94","author":"MC Drumond","year":"1994","unstructured":"Drumond MC, Kristal B, Myers BD, Deen WM. Structural basis for reduced glomerular filtration capacity in nephrotic humans. J Clin Invest. 1994;94(3):1187\u201395.","journal-title":"J Clin Invest"},{"issue":"6","key":"1155_CR20","doi-asserted-by":"publisher","first-page":"F639","DOI":"10.1152\/ajprenal.00383.2014","volume":"308","author":"WJ Liu","year":"2015","unstructured":"Liu WJ, Xu BH, Ye L, Liang D, Wu HL, Zheng YY, et al. Urinary proteins induce lysosomal membrane permeabilization and lysosomal dysfunction in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2015;308(6):F639.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"1155_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1053\/j.ajkd.2005.02.007","volume":"45","author":"CL Chen","year":"2005","unstructured":"Chen CL, Fang HC, Chou KJ, Lee JC, Lee PT, Chung HM, et al. Increased endothelin 1 expression in adult-onset minimal change nephropathy with acute renal failure. Am J Kidney Dis. 2005;45(5):818\u201325.","journal-title":"Am J Kidney Dis"},{"issue":"18","key":"1155_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025845","volume":"100","author":"Y Shimamura","year":"2021","unstructured":"Shimamura Y, Abe K, Maeda T, Ogawa Y, Takizawa H, Ishigami J, et al. Association between diuretic administration before diagnosis and incidence of acute kidney injury in patients with minimal change disease: A single-center observational study. Medicine (Baltimore). 2021;100(18):e25845.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1155_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/CM9.0000000000001218","volume":"134","author":"SP Lin","year":"2020","unstructured":"Lin SP, Zhu FG, Meng JL, Sun XW, Cui J, Liang S, et al. Clinical features of acute kidney injury in patients with nephrotic syndrome and minimal change disease: a retrospective, cross-sectional study. Chin Med J (Engl). 2020;134(2):206\u201311.","journal-title":"Chin Med J (Engl)"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01155-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01155-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01155-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:01:54Z","timestamp":1783188114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01155-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01155-w","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yusuke Suzuki reports grants or contracts from Travere Therapeutics, Alexion Pharmaceuticals, Novartis Pharma, Tokiwa, Aurinia, Pfizer, and Rona Bioscience; consulting fees from Otsuka, Chinook (Novartis), Novartis, Argenx, Alexion, Renalys Japan, BioCryst, Alpine Immune Sciences, Takeda, Biogen, Vera, Viatris, Chugai, Bayer, and George Clinical (Emerald Clinical Trials); and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Kyowa Kirin, Novartis, Daiichi Sankyo, Tanabe Pharma, Boehringer Ingelheim, Otsuka, AstraZeneca, Calliditas, and Chinook (Novartis). The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This case report was conducted in accordance with the principles of the Declaration of Helsinki and its subsequent amendments. Ethical approval was not required for this type of study in accordance with institutional policies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal participants"}},{"value":"Written informed consent for publication was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"115"}}